New Advances in Flow Cytometry: From Diagnosis to Disease Monitoring in Acute Leukemia
A special issue of Cancers (ISSN 2072-6694).
Deadline for manuscript submissions: 13 November 2026 | Viewed by 160
Special Issue Editors
Interests: clinical hematology; acute leukemias; acute myeloid leukemia; immunophenotyping of hematological malignancies; allogeneic transplantation; measurable residual disease by flow cytometry and molecular techniques
Special Issues, Collections and Topics in MDPI journals
Interests: flow cytometry; myeloid and lymphoid neoplasms; molecular pathology
Special Issue Information
Dear Colleagues,
Flow-cytometry is a diagnostic technique that allows a multiparametric, fluorescence-based assessment of surface, cytoplasmic and nuclear antigen expression on a suspension of blood, bone marrow or solid-tissue cells. Besides playing a key role in acute leukemia lineage assessment, multiparametric flow cytometry (MFC) plays a fundamental role in response assessment through the evaluation of measurable residual disease (MRD). MRD has emerged as a powerful prognostic biomarker in acute leukemia, deeply influencing risk stratification, post-remission management, and transplant decision-making. Advances in MFC have increasingly enabled the sensitive detection of leukemic persistence, uncovering disease dynamics that are imperceptible with conventional morphology. Despite these technological developments, important challenges remain regarding standardization, interpretation, timing of assessments, and the integration of MRD into therapeutic algorithms across diverse patient populations.
This Special Issue will provide a comprehensive and updated overview of innovative flow-cytometric approaches in acute leukemia diagnosis and MRD monitoring, spanning methodological innovation, biological insight, and clinical application. We welcome original research articles and review manuscripts addressing the following: (1) innovative MFC techniques; (2) impact of artificial intelligence in computational flow-cytometry and cytometric big-data analysis; (3) novel MFC-based MRD detection technologies and harmonization efforts; (4) prognostic value of MRD across cytogenetic and molecular subgroups; (5) MRD-guided therapeutic strategies, including pre- and post-transplant interventions; (6) MRD in patients treated with non-intensive approaches; (7) real-world evidence and implementation challenges in routine practice.
By gathering high-quality contributions from translational researchers and clinicians, this Special Issue will refine the role of flow-cytometry in leukemia diagnosis and MRD detection to support its integration into personalized AML management.
We look forward to receiving your contributions.
Dr. Francesco Buccisano
Dr. Audi Francesca Setiadi
Dr. Raffaele Palmieri
Guest Editors
Manuscript Submission Information
Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as communications are invited. For planned papers, a title and short abstract (about 250 words) can be sent to the Editorial Office for assessment.
Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Cancers is an international peer-reviewed open access semimonthly journal published by MDPI.
Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2900 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.
Keywords
- flow cytometry
- multiparametric flow cytometry (MFC)
- acute leukemia
- measurable residual disease (MRD)
- prognostic biomarker
- MRD monitoring
Benefits of Publishing in a Special Issue
- Ease of navigation: Grouping papers by topic helps scholars navigate broad scope journals more efficiently.
- Greater discoverability: Special Issues support the reach and impact of scientific research. Articles in Special Issues are more discoverable and cited more frequently.
- Expansion of research network: Special Issues facilitate connections among authors, fostering scientific collaborations.
- External promotion: Articles in Special Issues are often promoted through the journal's social media, increasing their visibility.
- Reprint: MDPI Books provides the opportunity to republish successful Special Issues in book format, both online and in print.
Further information on MDPI's Special Issue policies can be found here.
